Westernization of lifestyle affects quantitative and qualitative changes in adiponectin

Mitsunobu Kubota1, Masayasu Yoneda1*, Norikazu Maeda2,3, Haruya Ohno1, Kenji Oki1, Tohru Funahashi2,3, Iichiro Shimomura2 and Noboru Hattori1

Abstract

Background: Although Japanese–Americans and native Japanese share the same genetic predispositions, they live different lifestyles, resulting in insulin resistance in Japanese–Americans. We investigated whether the quantitative and qualitative changes in adiponectin (APN) due to differences in lifestyle contribute to the development of insulin resistance.

Methods: We evaluated 325 native Japanese in Hiroshima, Japan and 304 Japanese–Americans in Los Angeles, the United States, who were aged between 30 and 70 years and underwent medical examinations between 2009 and 2010. All participants underwent a 75-g oral glucose tolerance test (OGTT) to assess their glucose tolerance. The insulin response to oral glucose load, the Matsuda index, total APN levels, and C1q-APN/total-APN ratios were compared between native Japanese and Japanese–Americans.

Results: Compared with the native Japanese, the Japanese–Americans had significantly lower Matsuda index and higher area under the curve values for serum insulin concentration during OGTT in the normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) groups, but not in the diabetes mellitus (DM) group. Furthermore, the Japanese–Americans had significantly lower total APN levels and higher C1q-APN/total-APN ratios than the native Japanese in the NGT and IGT groups, but not in the DM group.

Conclusions: This study suggested that, in Japanese people, the westernization of their lifestyle might affect quantitative and qualitative changes in APN and induce insulin resistance.

Keywords: Lifestyle westernization, Japanese migration, Insulin resistance, Total adiponectin, C1q-adiponectin

Background

Adiponectin (APN) is an adipose-specific protein which is exclusively secreted from adipose tissue into the peripheral blood. Circulating APN is considered to be a cardiometabolic marker associated with global cardiovascular risk [1]. Hypoadiponectinemia is closely associated with the risk for insulin resistance [2, 3], metabolic syndrome [4] and coronary artery disease [5, 6].

*Correspondence: masayone17@hiroshima-u.ac.jp
1 Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Japanese immigrants from Japan to the United States and their descendants [15]. Because Japanese–Americans, while genetically equivalent to native Japanese, have a different lifestyle, they are an appropriate population for investigating the effects of environmental changes on lifestyle-related metabolic diseases among Japanese people. In comparison with native Japanese living a Japanese lifestyle in Hiroshima, insulin resistance is more severe [16], and the prevalence of diabetes mellitus (DM) and metabolic syndrome is higher [17, 18] in Japanese–Americans living an American lifestyle in Hawaii or Los Angeles. We also reported that a low level of serum APN was a significant risk factor for type 2 DM [19]. Because decreased APN is associated with insulin resistance [2, 3], APN may be involved in insulin resistance induced by the westernization of lifestyles in Japanese people.

We hypothesized that not only the serum APN concentration but also the C1q-APN/total-APN ratio contributes to the higher degree of insulin resistance in Japanese–Americans compared with native Japanese. In this study, we compared insulin response to an oral glucose load, total APN levels, and C1q-APN/total-APN ratios between native Japanese and Japanese–Americans in order to determine the impact of the environmental factor of lifestyle on the quantitative and qualitative changes in APN.

**Methods**

**Study subjects**

This study included 325 native Japanese living in Hiroshima, Japan and 304 Japanese–Americans living in Los Angeles, USA, who were aged between 30 and 70 years and underwent medical examinations between 2009 and 2010. Those under drug treatment for DM or dyslipidemia, those with renal failure (an estimated glomerular filtration rate of <30 mL/min/1.73 m² according to the Japanese equation [20]), and those with a C-reactive protein (CRP) level ≥10 mg/L were excluded. All participants underwent a 75-g oral glucose tolerance test (OGTT). This study was conducted with the approval of the Ethics Committee of Hiroshima University.

**Anthropometric data and laboratory tests**

After overnight fasting, each participant was interviewed, provided written informed consent, and underwent a physical examination and venous blood collection. Body measurements were taken in the standing position. Body mass index (BMI) was calculated as weight (kg)/height (m²). Each blood sample was centrifuged, immediately frozen, and stored until measurement. Serum glucose levels were measured using the hexokinase method. Immunoreactive insulin (IRI) levels were measured using the double-antibody radioimmunoassay. Total cholesterol and triglyceride levels were measured using enzymatic assays. High-density lipoprotein (HDL) cholesterol levels were measured using a homogeneous assay. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation [21]. CRP levels were measured using the highly sensitive latex agglutination method. Total APN levels were measured using an enzyme-linked immunosorbent assay (ELISA) (human adiponectin ELISA kit; Otsuka Pharmaceutical Co., Tokushima, Japan). C1q-APN levels were measured using a previously reported ELISA method developed in a joint study by Osaka University and Otsuka Pharmaceutical Co. [12]. DM was diagnosed as a fasting serum glucose level ≥126 mg/dL (7.0 mmol/L) or a serum glucose level ≥200 mg/dL (11.1 mmol/L) at 2 h after OGTT. Normal glucose tolerance (NGT) was defined as a fasting serum glucose level <110 mg/dL (6.1 mmol/L) and a serum glucose level <140 mg/dL (7.8 mmol/L) at 2 h after OGTT. Impaired glucose tolerance (IGT) was diagnosed in participants who did not meet the criteria of either NGT or DM [22]. Smoking status was assessed by self-report.

The Matsuda index and the area under the curve (AUC) for serum IRI during OGTT (OGTT_AUC IRI) were used as insulin resistance indices. The Matsuda index was calculated using serum glucose and insulin levels at 0, 60, and 120 min after OGTT [23, 24]. The OGTT_AUC IRI was determined according to the trapezoidal method from insulin levels at 0, 60, and 120 min after OGTT.

**Statistical analyses**

Because of the skewed distribution of data on triglycerides, CRP, Matsuda index, OGTT_AUC IRI, total APN, and C1q-APN/total-APN ratios, these parameters were logarithmically transformed and analyzed. Continuous variables were compared by Student’s t test between two categories, or analysis of variance (ANOVA) among three categories; if they were found to be significant, the Tukey–Kramer method was used to assess the association between categories. Categorical variables were analyzed using chi² tests. Pearson’s correlation analysis and multiple regression analysis were performed to determine the associations between insulin resistance and the total APN level or the C1q-APN/total-APN ratio. P values <0.05 were considered statistically significant. All analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA).

**Results**

The baseline characteristics of the participants are shown in Table 1. The male-to-female ratio, age, and BMI were comparable between native Japanese and Japanese–Americans. The systolic blood pressure, diastolic blood pressure, and triglyceride and CRP levels were...
Table 1 Baseline characteristics of participants

|                        | Native Japanese | Japanese–Americans |
|------------------------|-----------------|--------------------|
| N (male/female)        | 325 (124/201)   | 304 (134/170)      |
| Age (years)            | 55.3 ± 11.5     | 55.5 ± 10.8        |
| BMI (kg/m²)            | 23.0 ± 2.99     | 23.2 ± 3.22        |
| Smoking (none/ex/current) | 226/53/46     | 172/81/51*         |
| SBP (mmHg)             | 124.4 ± 17.7    | 129.2 ± 18.1*      |
| DBP (mmHg)             | 77.6 ± 11.1     | 82.5 ± 11.7*       |
| Total cholesterol (mg/dL) | 208.8 ± 34.4   | 212.6 ± 36.1       |
| HDL cholesterol (mg/dL) | 62.0 ± 14.5    | 61.1 ± 16.2        |
| LDL cholesterol (mg/dL) | 127.7 ± 31.5   | 129.7 ± 33.7       |
| Triglyceride (mg/dL)   | 88.0 (62.0–124.0) | 109.5 (77.3–156.8)* |
| CRP (mg/L)             | 0.31 (0.17–0.65) | 0.46 (0.24–1.06)*  |
| Fasting glucose (mg/dL) | 94.1 ± 11.4     | 91.8 ± 20.1        |
| 2-h glucose (mg/dL)    | 1196 ± 35.4     | 1188 ± 57.3        |
| Matsuda index (mU/L)   | 7.35 (4.84–9.98) | 6.06 (3.95–8.66)*  |
| Total APN (µg/mL)      | 8.84 (5.84–11.6) | 8.15 (5.50–11.3)*  |
| C1q-APN/total-APN ratio | 8.96 (7.12–11.6) | 10.2 (7.73–13.2)*   |

Data are presented as number, mean ± SD or median (25th–75th percentile levels)

BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL = high-density lipoprotein, LDL = low-density lipoprotein, CRP = C-reactive protein, NGT = normal glucose tolerance, IGT = impaired glucose tolerance, DM = diabetes mellitus, APN = adiponectin

* P < 0.05 native Japanese vs. Japanese–Americans

Discussion

In the 2009–2010 medical survey, insulin resistance, total APN level, and C1q-APN/total-APN ratio, which is a new potential biomarker based on C1q-APN levels, were compared between two cohorts of Japanese people who shared the same genetic predispositions but lived different lifestyles; that is, Japanese–Americans living an American lifestyle in Los Angeles and native Japanese living a Japanese lifestyle in Hiroshima. The results of this study indicate that the westernization of lifestyles in Japanese may be associated with insulin resistance through the influence of APN abnormalities.

Insulin resistance and APN abnormalities

At first, we investigated the patterns of insulin response to oral glucose load according to glucose tolerance status in both Japanese cohorts. Ethnic differences in insulin secretion and insulin sensitivity have been reported.
**Fig. 1** Insulin response to oral glucose load and insulin resistance in native Japanese and Japanese–Americans. Serum IRI levels during OGTT in native Japanese (a) and Japanese–Americans (b). The NGT group is indicated by dots and solid line, the IGT group as triangles and bold dotted line, and the DM group as squares and thin dotted line. *P < 0.05 compared with NGT group. Summary of OGTT AUC IRI values (c) and Matsuda index (d) by glucose tolerance status between native Japanese and Japanese–Americans. The line in the middle of the box indicates the median value; the box extends from the 25th–75th percentiles. IRI immunoreactive insulin, OGTT AUC IRI area under the curve for serum IRI during OGTT, NJ native Japanese, J–A Japanese–Americans, NGT normal glucose tolerance, IGT impaired glucose tolerance, DM diabetes mellitus.

**Fig. 2** Summary of total APN level and C1q-APN/total-APN ratio by glucose tolerance status between native Japanese and Japanese–Americans. The line in the middle of the box indicates the median value; the box extends from the 25th–75th percentiles. APN adiponectin, NJ native Japanese, J–A Japanese–Americans, NGT normal glucose tolerance, IGT impaired glucose tolerance, DM diabetes mellitus.
between Japanese and Caucasians [25]. In the present study, we revealed that the total serum insulin concentration during OGTT was significantly higher in the Japanese–Americans than in the native Japanese in the NGT and IGT groups but not in the DM group.

Subsequently, we measured serum concentrations of total APN and C1q-APN to investigate not only the quantity (total APN level) but also the quality (C1q-APN/total-APN ratio) of APN in both Japanese cohorts. As a result, both total APN levels and C1q-APN/total-APN ratios were significantly associated with the Matsuda index in the native Japanese and also in the Japanese–Americans. This indicates that the quantitative and qualitative changes in APN could relate insulin resistance in Japanese people regardless of their living countries.

However, compared with the native Japanese, the Japanese–Americans had lower total APN levels and higher C1q-APN/total-APN ratios. Furthermore, the analyses according to glucose tolerance status showed significant differences between these cohorts except for those in the DM group. The impact of the differences in lifestyles on insulin resistance and APN abnormalities appeared to have been clearly exhibited in the NGT and IGT groups. The possible reasons for the lack of a significant difference in the DM group include the potential difficulty in detecting changes in APN levels owing to lifestyle alone because APN are strongly affected by DM in both native Japanese and Japanese–Americans and the possibility that the lifestyle of native Japanese with DM is becoming similar to that of Japanese–Americans.

**Inflammation and APN abnormalities**

Next, the association between chronic low-grade inflammation and insulin resistance has been reported [26]. In fact, serum CRP levels were higher in the Japanese–Americans than in the native Japanese in the present study (Table 1). In addition, total APN levels are reportedly lower in severe inflammatory states [27]. Thus, inflammation is highly likely to be involved at least in part with APN abnormalities and insulin resistance. Because adipose tissue excessively produces complement C1 in obesity, the complement system may be associated with the inflammation of adipose tissue and insulin resistance [28]. The association with insulin resistance is also suggested by a finding that the C1q-APN/total-APN ratio is a useful marker for metabolic syndrome [12]. Accordingly, the high C1q-APN/total-APN ratios in Japanese–Americans may indicate that APN binds to the inflammatory molecule C1q and inhibits inflammation to play a protective role in the chronic inflammatory state resulting from an American lifestyle.

**Study limitations**

In this study, we did not evaluate high-molecular weight (HMW)–APN which is the most biologically active form of APN. A previous report showed that the serum HMW-APN level and the C1q/HMW-APN ratio were independent markers of coronary artery stenosis [29]. Another limitation of this study was that its cross-sectional study design does not clearly show causal relationships. To investigate the direct impact of westernized lifestyles,
future prospective longitudinal studies are necessary. In addition to westernized lifestyles, APN characteristics may be influenced by various factors such as genetic [30] and so on. Furthermore, this study included only native Japanese and Japanese–Americans but did not examine other ethnic groups.

Conclusions
In Asians including Japanese, even mild obesity poses a risk of DM [31]. As one of the causes of the increased incidence of DM in Japanese, in whom the prevalence of obesity is lower than in Europeans and Americans, the results of this study suggest that the westernization of their lifestyles might have caused both quantitative and qualitative changes in APN, which might have resulted in the induction of insulin resistance and increased risk for the development of DM.

Additional file

Additional file 1: Table A. Relationships of Matsuda Index by regression analysis with total APN (A) and C1q-APN/total-APN ratio (B) as the dependent variables in native Japanese and Japanese-Americans.

Abbreviations
APN: adiponectin; C1q-APN: C1q-adiponectin complex; DM: diabetes mellitus; CRP: C-reactive protein; OGTT: oral glucose tolerance test; BMI: body mass index; IRI: immunoreactive insulin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ELISA: enzyme-linked immunosorbent assay; NGT: normal glucose tolerance; IGT: impaired glucose tolerance; AUC: area under the curve; HMW-APN: high-molecular weight adiponectin.

Authors’ contributions
MK collected, analyzed and interpreted the data, and wrote the manuscript. MY planned study design, evaluated and interpreted the data, and revised the manuscript. NM collected the data of C1q-adiponectin and total adiponectin, and edited the manuscript. HO and KO revised the manuscript. TF, IS, and NH collected, analyzed and interpreted the data, and wrote the manuscript. NM collected the data of C1q-adiponectin and total adiponectin, and edited the manuscript. HO and KO revised the manuscript. TF, IS, and NH reviewed the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. 2 Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan. 3 Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Osaka, Japan.

Acknowledgements
We thank the members of the Hiroshima Kenjin-kai Association of Southern California for their participation in this study. We are indebted to Drs. Kazufumi Ishida and Yui Usui from the Hiroshima General Hospital and Ms. Kayoko Ohashi from the Department of Metabolic Medicine, Graduate School of Medicine, Osaka University for the sample assays. We also thank Mr. Maiko Kubota from the Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University for her writing assistance on this manuscript.

Competing interests
NM and TF are members of the “Department of Metabolism and Atherosclerosis”, a sponsored course endowed by Kowa Co. Ltd. The company has a scientific officer who oversees the program. All other authors declare no competing interests. Human serum C1q-binding adiponectin complex assay is under patent application in Japan.

Availability of data and materials
The datasets used/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocols were approved by the Ethics Committee of Hiroshima University, and written informed consent was provided by all subjects.

Funding
This research was supported in part by Osaka University’s academia–industry collaboration policy position the collaboration between Osaka University and Otsuka Pharmaceutical Co., Ltd.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 May 2017 Accepted: 20 June 2017

Published online: 06 July 2017

References
1. Chiara TD, Argano C, Scaglione A, Corrao S, Pinto A, Scaglione R. Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk. Acta Cardiol. 2015;70:33–40.
2. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tatearanni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.
3. Medina-Urrutia A, Posadas-Romero C, Posadas-Sánchez R, Jorge-Galarza E, Villareal-Molina T, González-Salazar Mdel C, Cardoso-Saldaña G, Vargas-Alarcon G, Torres-Tamayo M, Juárez-Rojas JG. Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance. Cardiovasc Diabetol. 2015;14:20.
4. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.
5. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Anta Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Association of hyperadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–9.
6. Kawagoe J, Ishikawa T, Iwakini H, Date H, Imamura T, Kitamura K. Association between adiponectin production in coronary circulation and future cardiovascular events in patients with coronary artery disease. Int Heart J. 2014;55:239–43.
7. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. CDNA cloning and expression of a novel adipose specific collagen-like factor, aplM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–9.
8. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–9.
9. Ebina K, Oshima K, Matsuda M, Fukuhara A, Maeda K, Kihara S, Hashimoto J, Ochi T, Band A, Yoshikawa H, Shimomura I. Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. Biochem Biophys Res Commun. 2009;378:186–91.
10. Peake PW, Shen Y, Wolther A, Charlesworth JA. Adiponectin binds C1q and activates the classical pathway of complement. Biochem Biophys Res Commun. 2008;367:560–5.
11. Masai H, Ortani K, Yokoita T, Takahashi I, Shirogane T, Ujiie H, Ichii M, Saitoh N, Maeda T, Tanigawa R, Oka K, Hoshida Y, Tomiyama K, Kanakura Y. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp Hematol. 2007;35:947–56.
12. Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi T, Tanaka H, Akamatsu S, Funahashi T, Shimomura I. Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin/total adiponectin ratio. Metabolism. 2013;62:109–20.
13. Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I. Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics. Metabolism. 2013;62:376–85.
14. Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I. High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Metabolism. 2013;62:578–85.
15. Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC. Diabetes mellitus and its vascular complications in Japanese migrants on the Island of Hawaii. Diabetes Care. 1979;2:161–70.
16. Nakanishi S, Okubo M, Yoneda M, Jitsuiki K, Yamane K, Kohno N. A comparison between Japanese–Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother. 2004;58:571–7.
17. Hara H, Egusa G, Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese–Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract. 1994;24:537–42.
18. Yoneda M, Yamane K, Jitsuiki K, Nakanishi S, Kamei N, Watanabe H, Kohno N. Prevalence of metabolic syndrome compared between native Japanese and Japanese–Americans. Diabetes Res Clin Pract. 2008;79:518–22.
19. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decrease in total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese–Americans. J Clin Endocrinol Metab. 2006;91:3873–7.
20. Matsuo S, Inai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tominno Y, Yotokawa H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
22. Gennuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Leibovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.
23. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.
24. DeFronzo RA, Matsuda M. Reduced time points to calculate the composite index. Diabetes Care. 2010;33:e93.
25. Maller JB, Dalla Man C, Overgaard RV, Ingerslev SH, Tornoe CW, Pedersen M, Tanaoka H, Ohnsi M, Ueki K, Lyne J, Vasconcelos NM, Pedersen BK, Kadowaki T, Cobelli C. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab. 2014;99:4273–80.
26. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–9.
27. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretni H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–4.
28. Zhang J, Wright W, Bernlohr DA, Cushman SW, Chen X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2007;292:E1433–40.
29. Hong ES, Lim C, Choi HY, Xu EJ, Kim RM, Moon JH, Lim S, Park KS, Jang HC, Choi SH. The amount of C1q-adiponectin complex is higher in the serum and the complex localizes to perivascular areas of fat tissues and the intimamedial layer of blood vessels of coronary artery disease patients. Cardiovasc Diabetol. 2015;14:50.
30. Ortega Moreno L, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, Menzaghi C. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:17.
31. Chan JC, Malik V, Jia W, Kadovski T, Yajnik CS, Yoon K-H, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.